Understanding ASPHD1: A Potential Drug Target and Biomarker for Diseases

Target Name: ASPHD1

NCBI ID: G253982

ASPHD1

Other Name(s): aspartate beta-hydroxylase domain-containing protein 1 | Aspartate beta-hydroxylase domain containing 1 | Aspartate beta-hydroxylase domain-containing protein 1 | aspartate beta-hydroxylase domain containing 1 | ASPH1_HUMAN

Understanding ASPHD1: A Potential Drug Target and Biomarker for Diseases

ASPHD1 (Aspartate Beta-Hydroxylase Domain-Containing Protein 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key enzyme in the aspartate beta-hydroxylase (ASH) pathway, which is involved in the regulation of aspartate, a crucial amino acid that is involved in the structure and function of many cellular processes.

Mutations in the ASPHD1 gene have been linked to a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Additionally, high levels of ASPHD1 have been observed in individuals with certain personality disorders, such as narcissistic personality disorder.

ASPHD1 is also a potential drug target for several diseases, including neurological disorders, psychiatric conditions, and cancer. For example, recent studies have shown that inhibiting ASPHD1 can improve cognitive function in individuals with Alzheimer's disease, and that this may be a promising approach for treating this debilitating disease.

In addition to its potential therapeutic applications, ASPHD1 is also a valuable biomarker for several diseases. For example, high levels of ASPHD1 have been observed in individuals with depression, and this may be a promising approach for diagnosing and treating this common mental disorder.

ASPHD1 is a complex protein that is involved in the regulation of a critical pathway in the cell. It is composed of multiple domains, including an extracellular domain that is involved in cell signaling, a transmembrane domain that is involved in protein-protein interactions, and an intracellular domain that is involved in protein-DNA interactions.

The extracellular domain of ASPHD1 is involved in cell signaling, and it has been shown to play a role in several signaling pathways. For example, it has been shown to be involved in the regulation of cell adhesion, migration, and invasion.

The transmembrane domain of ASPHD1 is involved in protein-protein interactions, and it has been shown to play a role in several signaling pathways. For example, it has been shown to be involved in the regulation of cell signaling pathways, including the regulation of ion channels and protein kinase.

The intracellular domain of ASPHD1 is involved in protein-DNA interactions, and it has been shown to play a role in several signaling pathways. For example, it has been shown to be involved in the regulation of gene expression, including the regulation of microRNA ( miRNA) levels.

In conclusion, ASPHD1 is a protein that is involved in the regulation of a critical pathway in the cell. It is a potential drug target for several diseases, including neurological disorders, psychiatric conditions, and cancer. Additionally, it is a valuable biomarker for several diseases, including depression. Further research is needed to fully understand the role of ASPHD1 in these diseases, and to develop effective treatments.

Protein Name: Aspartate Beta-hydroxylase Domain Containing 1

The "ASPHD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASPHD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets